Preclinical and Toxicology Studies of 1263W94, a Potent and Selective Inhibitor of Human Cytomegalovirus Replication

1263W94 is a novel benzimidazole compound being developed for treatment of human cytomegalovirus infection. No adverse pharmacological effects were demonstrated in safety pharmacology studies with 1263W94. The minimal-effect dose in a 1-month rat study was 100 mg/kg/day, and the no-effect dose in a...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Koszalka, George W., Johnson, Nelson W., Good, Steven S., Boyd, Leslie, Chamberlain, Stanley C., Townsend, Leroy B., Drach, John C., Biron, Karen K.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Microbiology 2002
Matèries:
Antiviral Agents
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC127362/
https://ncbi.nlm.nih.gov/pubmed/12121907
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.46.8.2373-2380.2002
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars